This content was funded by Johnson & Johnson. This material is intended for educational and scientific exchange purposes only. It is not intended to be promotional and should not be used to make treatment decisions for any individual patient. The views expressed are those of the speaker and do not necessarily reflect those of Johnson & Johnson.

Atypical EGFR mutations make up approximately 5 to 10% of EGFR-mutant NSCLC, and because some assays only report exon 19 deletions and L858R, they are easy to miss. In this short podcast, Melina Marmarelis, thoracic oncologist at the University of Pennsylvania, explains why these mutations often respond differently to EGFR TKIs and how to pick them up on NGS. She also walks through CHRYSALIS-2 Cohort C, which evaluated amivantamab plus lazertinib in treatment-naive and previously treated patients.

Explore:

• Why G719X and other atypical mutations alter the ATP-binding pocket differently from exon 19 del and L858R • Which assays can miss atypical mutations, and when broader NGS is needed • What CHRYSALIS-2 Cohort C evaluated, and the limitations of a single-arm phase 1/1b study • How the ASCO living guideline now addresses atypical EGFR alterations

Amivantamab plus lazertinib is not approved by the US Food and Drug Administration for the treatment of atypical EGFR-mutated non-small cell lung cancer. This content includes discussion of investigational and unapproved uses. The data presented do not establish safety or efficacy for any unapproved use. Prescribers should consult the full Prescribing Information for approved indications and complete safety information.

Speaker:

Melina E. Marmarelis, Associate Professor of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

In this quickfire episode, Linda Wesp answers rapid-fire questions on gender-affirming care, HIV, culturally safe healthcare, and LGBTQIA+ health. Discover practical insights on tackling stigma, improving clinician education, and creating more inclusive healthcare environments in just a few minutes.

Linda Wesp joins host Catherine Glass to discuss how clinicians can deliver culturally safe, gender-affirming healthcare across all areas of practice. From informed consent models and trauma-informed care to supporting patients who are transgender and gender-diverse, this episode explores practical approaches to improving healthcare experiences and outcomes.

Timestamps:

01:03 – The historical timeline of gender-affirming care

04:49 – Gender-affirming care outside of specialist clinics

07:06 - Breaking down misconceptions of gender-affirming care

09:25 – Informed consent models

13:30 – Culturally safe care

17:59 – Listening to transgender youth

20:36 – Creating trauma informed environments

In the final episode, Tonia Poteat discusses how healthcare systems can move beyond recognising health inequities to implement meaningful change. From community-engaged research and inclusive policy development to the future priorities for transgender health research, this episode explores practical strategies for advancing equitable healthcare.

Timestamps:

01:00 – Translating Evidence Into Practice

05:30 – Policy Change and Challenging Healthcare Systems

Why do transgender communities continue to experience profound health inequities? In Part 2, Tonia Poteat examines the structural and social determinants influencing transgender health, the persistent disparities in HIV prevention and care, and the importance of addressing housing, employment, stigma, and gender affirmation alongside traditional healthcare interventions.

Timestamps:

01:01 – Political Determinants of Health

04:00 – Gender and Racial Minorities – HIV

06:04 – Why Intersectionality is Important in HIV Care

08:52 – Responding to Non-Healthcare Challenges

Sagar Lonial discusses advances in multiple myeloma treatment, the evolving role of immunotherapy and minimal residual disease, unmet needs in relapsed disease, lessons from research, and emerging technologies shaping future care.

Timestamps:

00:00 – Introduction 01:24 – Inspiration for Myeloma Research 03:20 – Transformative Myeloma Treatment Developments 05:03 – Translating Science into Treatment 07:41 – Future of Immunotherapy in Myeloma 09:45 – Unmet Needs After Relapse 10:53 – Lessons from Research Setbacks 13:05 – Future Role of MRD Assessment 15:50 – Fostering Research Innovation 17:50 – Emerging Advances in Myeloma 19:45 – Three Wishes for Myeloma

Tonia Poteat joins host Catherine Glass to explore how intersectionality provides a more complete understanding of health inequities. Together, they discuss why single-axis approaches often fail, how overlapping identities shape health outcomes, and how clinicians can begin applying intersectional thinking to improve patient care and healthcare research.

Timestamps:

01:00 – Intersectionality

02:26 – Why Intersectionality is Important in HIV Care

04:13 – Intersectionality and Gender-Diverse People

In this rapid-fire episode, Tonia Poteat answers key questions on intersectionality, transgender health, and health equity. Discover what drives her work in LGBTQIA+ health, common misconceptions surrounding transgender healthcare, the biggest challenges facing transgender communities today, and the practical steps healthcare organisations can take to become more inclusive in just a few minutes.

In the final episode of this series, Dr Carl Streed Jr explores the evolving evidence base, risk assessment, and policy landscape in transgender healthcare. From cardiovascular outcomes and research challenges to the interpretation of emerging evidence in healthcare and sport, this episode examines how clinicians, researchers, and policymakers can translate evidence into guidance while advancing inclusive, equitable care.

Timestamps:

01:00 – Cardiovascular Risk in Transgender Patients

04:29 – Sports Governing Bodies

06:05 – Methodological Challenges

07:26 – Translating Evidence into Guidance

How can clinical practice evolve to deliver more inclusive gender-affirming care? In Part 2, Carl Streed Jr shares insights from his research on implementing equitable healthcare, including the impact of targeted education, barriers to care delivery, and the role of training programmes in building long-term clinical competence. A must-listen for clinicians seeking to understand the evidence, practice, and future of transgender healthcare.

Timestamps:

01:08 – Providing Training on Gender Affirming Care

02:32 – Barriers to Gender Affirming Care

03:29 – Well-Rounded Gender-Affirming Care

04:45 – When to Look at Sex, and When to Look at Affirmed Gender?

06:27 – Focusing on the Person and the Medicine

08:11 – Continuity of Care

10:20 – Advocacy